Results 211 to 220 of about 32,386 (229)

Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

Gastroenterology, 2007
Stephen B Hanauer, Remo Panaccione
exaly  

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Arthritis and Rheumatism, 2003
Michael E Weinblatt, Edward C Keystone, Larry W Moreland   +2 more
exaly  

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

Lancet, The, 2014
Josef S Smolen, Paul Emery, Roy M Fleischmann   +2 more
exaly  

Adalimumab

Reactions Weekly
  +4 more sources

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

Gut, 2014
C Janneke Van Der Woude
exaly  

Adalimumab

Reactions Weekly, 2012
openaire   +1 more source

Adalimumab

Reactions Weekly, 2016
  +4 more sources

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Gastroenterology, 2006
Stephen B Hanauer, Richard Fedorak, Milan Lukas   +2 more
exaly  

Adalimumab for the treatment of fistulas in patients with Crohn's disease

Gut, 2009
Remo Panaccione
exaly  

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Clinical Gastroenterology and Hepatology, 2016
B Ungar, Yarden Yavne, Ronen Loebstein
exaly